ArticleHaematologica2023
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
Open access · goldAbstract readLetter
In one paragraph
Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
7.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.Experimental hematology & oncology · 2026Article
- Advancements in diagnosis and treatments of acute leukemia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Targeted Therapies Combined with Intensive Chemotherapy in Fit Acute Myeloid Leukemia: Past Developments, Current Evidence, and Future Therapeutic Paradigms.Journal of clinical medicine · 2026Review
- Article
- Adapting measurable residual disease evaluation to clinical practice for patients with acute lymphoblastic leukemia who underwent allogeneic stem cell transplantation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Standardization of Measurable Residual Disease in Acute Myeloid Leukemia by Flow Cytometry: A Multicenter Study.EJHaem · 2025Article
- Measurable residual disease-guided therapy in acute myeloid leukaemia: Practical insights.British journal of haematology · 2025Review
- Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know.Blood science (Baltimore, Md.) · 2025Review
- Pretransplant MRD does not seem to affect survival in NPM1-mutated AML undergoing allogeneic stem cell transplantation.Blood advances · 2025Article
- Acute Myeloid Leukemia-Use of Measurable Residual Disease to Improve Outcomes.Advances in experimental medicine and biology · 2025Review
- Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.Hematology. American Society of Hematology. Education Program · 2024Review
- Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual disease.bioRxiv : the preprint server for biology · 2024Article
- Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.Bone marrow transplantation · 2024Article
- Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions.Biomedicines · 2024Review
- Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.Leukemia · 2024Article
- Article
- Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.Blood cancer discovery · 2024Review
- Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment.Frontiers in pharmacology · 2024Review
- Understanding differential technologies for detection of MRD and how to incorporate into clinical practice.Hematology. American Society of Hematology. Education Program · 2023Article
- Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?Haematologica · 2023Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 13 institutions in 8 countries.
Jesse M TetteroAmsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands.
Lok Lam NgaiAmsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands.
Costa BachasAmsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands.
Dimitri A BreemsZiekenhuis Netwerk Antwerpen, Antwerp, Belgium.
Thomas FischerOtto von Guericke University Hospital Magdeburg, Magdeburg, Germany.
Bjorn T GjertsenHaukeland University Hospital, Bergen, Norway.
Patrycja GradowskaDutch-Belgian Hemato-Oncology Cooperative Group Data Center-Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Laimonas GriskeviciusVilnius University Hospital Santaros Klinikos and Vilnius University, Vilnius, Lithuania.
Jeroen J W M JanssenAmsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands.
Gunnar JuliussonSkanes University Hospital, Lund, Sweden.
Johan MaertensUniversity Hospital Gasthuisberg, Leuven, Belgium.
Markus G ManzUniversity Hospital, Zurich, Switzerland; Swiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland.
Thomas PabstSwiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland; Department of Medical Oncology, Inselspital; University Hospital, Bern, Switzerland.
Jakob PasswegSwiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland; University Hospital, Basel, Switzerland.
Kimmo PorkkaHelsinki University Hospital Cancer Center, Helsinki, Finland.
Peter J M ValkErasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Bob LöwenbergErasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Gert J OssenkoppeleAmsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands.
Jacqueline CloosAmsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands. j.cloos@amsterdamumc.nl.
Amsterdam University Medical Centers · NLCancer Center Amsterdam · NLErasmus MC Cancer Institute · NLSwiss Group For Clinical Cancer Research · CHErasmus MC · NLHaukeland University Hospital · NOHelsinki University Hospital · FISkåne University Hospital · SEUniversitair Ziekenhuis Leuven · BEUniversity Hospital Magdeburg · DEUniversity Hospital of Basel · CHVilnius University · LTZiekenhuisnetwerk Antwerpen Stuivenberg · BE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteHumansNeoplasm, ResidualRecurrenceTransplantation ConditioningTransplantation, Homologous
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.